research Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
Search
for
Sort by
Research
390-420 / 1000+ results 
research Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Novel inhibitors of 5α-reductase
New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
research Experimental Assessment of 3-meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors in silico and in vivo Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
research Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates
Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
research Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
research 11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis
11β-Hydroxylase inhibitors help prevent seizures in mice by boosting natural neurosteroid production.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2
Cepharanthine and tetrandrine show promise as COVID-19 drugs.
research The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles.
CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Letter to the Editor: A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Healthcare System
Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
research CFTR potentiator ivacaftor protects against noise-induced hair cell loss by increasing Nrf2 and reducing oxidative stress
Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
research JAK-inhibitors in dermatology: current evidence and future applications
JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
research Discovery of novel 5α-reductase type II inhibitors by pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulations
A new compound may treat benign prostatic hyperplasia better than finasteride.
research The role of janus kinases in the treatment of autoimmune skin diseases
Janus kinase inhibitors show promise in treating autoimmune skin diseases.
research 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research Targeting telomeric RNA quadruplexes with natural metabolites to prevent cancer
research Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa
Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)
AH-001 could be a safer and more effective treatment for hair loss.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research 5PSQ-056 Experience with tofacinitib and baricitinib in rheumatoid arthritis
Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
research Synthesis and biological evaluation of esters of 16-formyl-17-methoxy-dehydroepiandrosterone derivatives as inhibitors of 5α-reductase type 2
Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.